Increased risk for CV events and severe hypoglycemia in T2D patients treated with β-blockers seems reason enough to rethink this Rx.
Are you a US-based MD who sees patients with diabetes and likes to write? Why not blog for EndocrinologyNetwork.com? Be heard on topics that keep you up at night. Contact us here and we can send you the details.